Amplia Therapeutics Launches Phase 2b Trial for Narmafotinib
Key points
- Initiates Phase 2b study of narmafotinib in pancreatic cancer
- New daily dosing regimen combined with standard chemotherapies
- Patient enrollment planned to start by Q4 2026
Full summary
Amplia Therapeutics Limited, an Australian pharmaceutical company, has announced the initiation of a Phase 2b study for narmafotinib, a FAK inhibitor, in pancreatic cancer. The study builds on data from previous trials and will explore a new daily dosing regimen in combination with standard chemotherapies, gemcitabine and Abraxane. The trial is designed to serve as the first stage of a registrational study and aims to address the unmet need for innovative treatments in pancreatic cancer. Patient enrollment is expected to begin by the fourth quarter of 2026, with initial safety and tolerability assessments planned for the second quarter of 2027.
Guidance
null
Outlook
null
Summary generated by a large language model. Please interpret with care.